CD8+ T‐cell‐mediated JAK–STAT, NF‐κB, and MAPK signaling pathways are enriched in IPF patients [168], with inhibitors of these pathways showing therapeutic promise. This evidence concerns the gene SOAT1 and idiopathic pulmonary fibrosis.